Open AccessDifferential Regulation of MMP‐9 and TIMP‐2 Expression in Malignant Melanoma Developed in Metallothionein/RET Transgenic Mice
Author(s) -
Asai Masami,
Kato Masashi,
Asai Naoya,
Iwashita Toshihide,
Murakami Hideki,
Kawai Kumi,
Nakashima Izumi,
Takahashi Masahide
Publication year - 1999
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1999.tb00670.x
Subject(s) - matrix metalloproteinase , metallothionein , melanoma , downregulation and upregulation , malignant transformation , pathology , cancer research , genetically modified mouse , biology , transgene , medicine , gene , biochemistry
We recently established a metallothionein‐I(MT)/RET transgenic mouse line in which skin melanosis, benign melanocytic tumor and malignant melanoma develop stepwise. Malignant melanoma cells but not benign melanocytic tumor cells had metastatic ability in transgenic mice. In the present study, we investigated the expression of several matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) , including MMP‐1, MMP‐2, MMP‐3, MMP‐7, MMP‐9, MT1– MMP, TIMP‐1 and TIMP‐2 , in these tumors. Western and northern blot analyses revealed that malignant transformation of melanocytic tumors developed in MT/RET transgenic mice accompanied with upregulation of MMP‐9 and downregulation of TIMP‐2. Expression of other MMP and TIMP genes examined was very low or undetectable in both benign and malignant tumors. Since activation of MMP‐9 in malignant tumors was detected by gelatin zymography, these results suggest that imbalance of expression of the MMP‐9 and TIMP‐2 genes might be associated with metastatic ability of melanoma cells developed in MT/RET transgenic mice.